We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

16 hedge funds and large institutions have $5.43M invested in Hepion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

3% less capital invested

Capital invested by funds: $5.6M → $5.43M (-$173K)

38% less funds holding

Funds holding: 26 → 16 (-10)

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

Holders
16
Holders Change
-10
Holders Change %
-38.46%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
4
Closed
12
Calls
$46K
Puts
–
Net Calls
+$46K
Net Calls Change
-$98K

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$1.9M
2
Morgan Stanley
Morgan Stanley
New York
+$233K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$84.7K
4
BlackRock
BlackRock
New York
+$68.7K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$25.8K

Top Sellers

Rank Fund Capital Flow
1
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$122K
2
Northern Trust
Northern Trust
Illinois
-$103K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$68.9K
4
ML
McAdam LLC
Pennsylvania
-$48.3K
5
PAM
PVG Asset Management
Colorado
-$47.5K

HEPA Hedge Fund Activity: Q2 2023 in Review

16 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2023, worth a combined $5.43M — down 3.1% from $5.6M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of HEPA and 2 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $1.9M. The largest seller was Envestnet Asset Management, exiting entirely with an estimated $122K sold.

  • 16 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2023, down from 26 in Q1 2023.
  • Funds reported $5.43M of Hepion Pharmaceuticals stock for Q2 2023, down 3.1% quarter-over-quarter.
  • 2 funds opened new Hepion Pharmaceuticals positions in Q2 2023 and 12 closed out, a net change of -10 holders.
  • The largest Hepion Pharmaceuticals buyer in Q2 2023 was Octagon Capital Advisors, an estimated $1.9M added.
  • The largest Hepion Pharmaceuticals seller in Q2 2023 was Envestnet Asset Management, an estimated $122K sold.

Based on aggregated 13F filings for Q2 2023.